Abstract
Background
The wide spread of carbapenem-resistance clones of Acinetobacter baumannii has made it a global public problem. Some studies have shown that the prevalence of Acinetobacter baumannii clones can change over time. However, few studies with respect to the change of epidemiological clones in Acinetobacter baumannii during Corona Virus Disease 2019 (COVID-19) were reported. This study aims to investigate the molecular epidemiology and resistance mechanisms of Acinetobacter baumannii during COVID-19.
Results
A total of 95 non-replicated Acinetobacter baumannii isolates were enrolled in this study, of which 60.0% (n = 57) were identified as carbapenem-resistant Acinetobacter baumannii (CRAB). The positive rate of the blaOXA−23 gene in CRAB isolates was 100%. A total of 28 Oxford sequence types (STs) were identified, of which the most prevalent STs were ST540 (n = 13, 13.7%), ST469 (n = 13, 13.7%), ST373 (n = 8, 8.4%), ST938 (n = 7, 7.4%) and ST208 (n = 6, 6.3%). Differently, the most widespread clone of Acinetobacter baumannii in China during COVID-19 was ST208 (22.1%). Further study of multidrug-resistant ST540 showed that all of them were carrying blaOXA−23, blaOXA−66, blaADC−25 and blaTEM−1D, simultaneously, and first detected Tn2009 in ST540. The blaOXA−23 gene was located on transposons Tn2006 or Tn2009. In addition, the ST540 strain also contains a drug-resistant plasmid with msr(E), armA, sul1 and mph(E) genes.
Conclusion
The prevalent clones of Acinetobacter baumannii in our organization have changed during COVID-19, which was different from that of China. ST540 strains which carried multiple drug-resistant mobile elements was spreading, indicating that it is essential to strengthen the molecular epidemiology of Acinetobacter baumannii.
Keywords: Acinetobacter baumannii, Molecular epidemiology, Resistance mechanisms, ST540, Tn2009
Introduction
Acinetobacter baumannii (A.baumannii) is a common opportunistic pathogen causing infections, including hospital-acquired pneumonia, bacteremia, urinary tract infections, and traumatic injuries [1]. Multiple intrinsic and acquired resistance mechanisms [2]have made multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) A. baumannii strains increasingly common and made treatment increasingly harder [3–5]. Due to its high rate of resistance to carbapenems, the list of bacterial pathogens in urgent need of novel antibiotics issued by the World Health Organization (WHO) ranked carbapenem-resistant A.baumannii as the highest priority in 2017 [6].
β-lactamases are the main reason for bacterial resistance to carbapenems and could be classified into class A, class B, class C and class D [7]. Carbapenems belong to class D β-lactamases, which consist of blaOXA−23−like, blaOXA−40−like, blaOXA−51−like, blaOXA−58−like, and blaOXA−23. They are the leading cause of carbapenem resistance in A. baumannii [8]. Some studies have shown that the blaOXA−23 gene is the most prevalent class D β-lactamases gene [9] and can be inserted into the plasmid or chromosome so that A. baumannii can acquire drug resistance quickly [10]. The blaOXA−23 gene is usually located in transposons Tn2006, Tn2007, Tn2008, and Tn2009. Tn2006 is the most common type of transposons worldwide, while Tn2009 is mainly popular in China [11]. In addition, plasmids carrying resistance genes can help A.baumannii reduce antibiotic susceptibility and better adapt to the environment [12].
To better elucidate the molecular epidemiology of pathogens, Maiden et al. invented the Multilocus Sequence Typing (MLST) method in 1998 [13]. The MLST has now been applied in molecular epidemiology for disease transmission and virulence evolution, surveillance in public health, and many other fields [14–16]. According to the results of epidemiological studies on A. baumannii, CRAB has increased globally due to the worldwide prevalence of Global Clone 1 (GC1) and Global Clone 2 (GC2) [9]. CRAB has different mainstream STs in different regions. ST191, ST195, and ST208 are common STs in China [17, 18], and all three STs originated from GC2. The main prevalent clone in Italy is ST78 [19], and in central Greece, ST101 [20], while in the United States, ST208 and ST281 are predominant [21].
Studies have shown that drug resistance in A.baumannii is associated with predominant STs [22], and the predominant ST type of A.baumannii in the same region could be replaced by others with a higher growth rate [23]. Previously, we conducted molecular epidemiological studies on A.baumannii collected over a long period in a Beijing hospital. In this study, we found ST191 was replaced by other ST and demonstrated an outbreak of infection with ST195 carrying the blaOXA−23 resistance gene in northern China for the first time [24]. To our knowledge, there have been few studies on the long-term epidemic evolution of A.baumannii in a single medical machine, especially after the outbreak of COVID-19. Therefore, this study aimed to investigate the molecular epidemiology and resistance mechanisms of Acinetobacter baumannii in a single institution. The findings of this work will provide important insights for controlling the spread of CRAB and minimizing the incidence of untreatable infections in clinical settings.
Methods
Strain and identification
From January 2020 to December 2022, 95 strains of A.baumannii were collected from a single hospital in Beijing, China. Only the first isolate from each patient was included in the study. The samples were obtained from sputum, abdominal/pleural fluid, blood, urine, throats, and so on, all of which were initially identified as Acinetobacter spp. by the VITEK-2 system (BioMérieux France) and later identified to the species level by Microflex LT Time-of-Flight Mass Spectrometer.
Antimicrobial susceptibility tests
All A. baumannii strains were tested for susceptibilities to 15 antibiotics, including ticarcillin/clavulanic acid (TCC), piperacillin/tazobactam (TZP), ceftazidime (CAZ), cefoperazone/sulbactam (CFP), cefepime (FEP), imipenem (IPM), meropenem (MEM), tobramycin (TOB), ciprofloxacin (CIP), levofloxacin (LVX), tigecycline (TGC), colistin (COL), minocycline (MNO), doxycycline (DOX) and trimethoprim/sulfamethoxazole (TMP), using a VITEK-2 compact system with AST-N-335 cards. The results were evaluated according to the Clinical and Laboratory Standards Institute (CLSI) criteria (M100-S32).
Genome sequencing
Takara DNA extraction kit was used to extract the genomic DNA of the 95 strains. All strains were whole genome sequenced using the Illumina Hiseq X10 platform, with the 2*150 bp paired-end sequencing strategy. The genome was assembled and annotated using SPAdes [25] and Prokka [26].
Phylogenetic analysis
Single-nucleotide polymorphisms (SNPs) were extracted using Snippy (https://github.com/tseemann/snippy) to generate core genomic alignment. The core genomic alignment was used to generate a maximum likelihood (ML) phylogenetic tree by using Fasttree2 [27] (MDR-ZJ06 [28] as a reference sequence). And the results were shown by iTOL [29].
Multilocus sequence typing (MLST)
MLST analyses were performed using the Oxford and Pasteur scheme. The sequence types (STs) and allelic profiles were analyzed using the PubMLST database (http://pubmlst.org/abaumannii/ ). The newly identified STs were submitted to the MLST database curator for approval, and an ST number was assigned. A minimum-spanning tree based on the allelic difference between isolates of the seven housekeeping genes was constructed using PHYLOViZ Online [30].
Identification of resistance genes and drug-resistant mobile elements
All the antimicrobial resistance genes were identified using the Resfinder [31] software. We take the assembled contigs of ST540 genomes to the VRprofile2 pipeline [32] (https://tool2-mml.sjtu.edu.cn/VRprofile/) to classify contigs as the fragments of chromosomes or plasmids and to identify whether they carried resistance genes. To further study the plasmids with resistance genes, we used blastn to compare these contigs to the NCBI RefSeq plasmids database (https://ftp.ncbi.nlm.nih.gov/refseq/release/plasmid/) to find the reference sequence. For the drug-resistant plasmid of ST540, we use p2BJAB07104 (NC_021728.1) with 84% coverage and 100% identity as reference sequences to study the plasmid structure. Mauve [33] was used to identify all the contigs located in the resistant plasmid, by comparing strain contigs with the reference genome BJAB07104 (NC_021726.1) which contains the plasmid p2BJAB07104 (NC_021728.1). Plasmid maps were presented using BRIG [34]. To determine whether the contig carrying blaOXA−23 gene contains insertion sequences, we submitted it to ISfinder [35](http://www-is.biotoul.fr). To further identified the type of transposon of contigs carrying the blaOXA−23 gene, we compared these contigs with transposon reference sequences (Tn2006 EF127491.1, Tn2007 EF059914.1, Tn2008 KP074966.1, Tn2009 CP097879.1) using BLAST (ncbi-blast-2.11.0).
Results
Molecular epidemiology
A total of 95 non-repeating A.baumannii strains collected from January 2020 to December 2022 were enrolled in this study. The result of the MSLT Pasteur scheme showed that a total of 21 STs were found and the prevalent ST was ST2 (n = 56, 58.9%), ST40 (n = 9, 9.5%), and ST33 (n = 4, 4.2%). The Oxford scheme identified 28 STs, the most prevalent STs were ST540 (n = 13, 13.7%), ST469 (n = 13, 13.7%), ST373 (n = 8, 8.4%), ST938 (n = 7, 7.4%) and ST208 (n = 6, 6.3%). In this study, more than half of A. baumannii came from ICU (n = 56, 58.9%), followed by hepatological surgery (n = 17, 17.9%). The most common source of samples was sputum (n = 73, 65.7%) Fig. 1. As shown in Fig. 2, the detection rate of ST540 was equivalent to that of ST469. However, we could not find any strain belonging to ST469 in 2022.
Fig. 1.
Evolutionary relationship of 95 strains of Acinetobacter baumannii. The evolutionary relationships of the 95 Acinetobacter baumannii strains were represented using an evolutionary tree, with the circles from inner to outer being: year of isolation, oxf ST, pas ST, hospital ward, and sampling site
Fig. 2.

Top 5 ST-type detection rate. The horizontal and vertical coordinates represent the detection rate and the year of detection
To investigate the clonal evolution of A.baumannii during COVID-19, we studied the molecular epidemiology of A. baumannii in China (published on the NCBI website) from 2020 to 2022 and then performed a minimum-spanning tree analysis. The results showed that ST208(n = 68, 22.1%) was the most prevalent clone in China during this period, which is different from our findings (Fig. 3).
Fig. 3.
ST-type minimum-spanning tree. (A) Genetic relationship of most Acinetobacter baumannii isolates of China. (B) genetic relationship of Acinetobacter baumannii isolates of this study. The size of the dots is proportional to the number of strains
Antimicrobial susceptibility tests
The minimal inhibitory concentration (MIC) values against 15 kinds of drugs were determined for all A. baumannii. Figure 4 A shows the drug resistance rate of 95 A. baumannii strains. The results showed that most A. baumannii strains were carbapenem-resistant A. baumannii (CRAB), with 58.9% against imipenem and 62.1% against meropenem. All isolates were susceptible to colistin, and 12 (12.6%) strains were resistant to tigecycline. Figure 4 B shows the resistance rates of the top 5 STs of strains. The antibiotic resistant rates of ST540, ST469, ST 938 and ST208 against carbapenems were above 80%, but all ST373 strains were sensitive to carbapenems. ST540 has the highest resistance rate to cefoperazone/sulbactam, reaching 78.5%.
Fig. 4.
Rates of antimicrobial resistance among isolates. (A)Shows the 95 strains of Acinetobacter baumannii ‘s overall antimicrobial resistance rate, and (B) shows the resistance rate of the top 5 ST types of detection rate
Drug-resistance genes
Genomic analysis showed that 95 A. baumannii contained a total of 30 resistance genes. The carbapenemase gene blaOXA−25 was present in all A. baumannii, and blaOXA−23 and blaOXA−66 were present in all CRAB isolates. The other resistance genes detected in our study included: carbapenem (blaNDM−1, blaOXA−106, blaOXA−120, blaOXA−121, blaOXA−217, blaOXA−23, blaOXA−259, blaOXA−343, blaOXA−374, blaOXA−377, blaOXA−430, blaOXA−51, blaOXA−66, blaOXA−78, blaOXA−98, blaTEM−1D), aminoglycoside (aac [3]-Ia, aph(3’)-Ia, aph(3’ ‘)-Ib, aph(6’)-Id, aph(3’)-VI, armA), macrolide (mph(E), msr(E)), phenicol (catB8), tetracycline (tet(B)) and sulfonamide (sul1, sul2) (Fig. 5). Interestingly, the ST540 strains contain a different resistance gene profile, some ST540 strains do not carry catB8, mph(E), msr(E) genes.
Fig. 5.
Heat map of antimicrobial resistance genes. Different colors in the legend on the left represent different oxf ST types. The blue portion of the heatmap indicates antimicrobial drug susceptibility testing, dark blue indicates resistance, light blue indicates intermediary, white indicates susceptibility, and gray indicates vacancy. The black portion of the heatmap represents resistance genes, black indicates the presence of the gene, and white indicates the absence of the gene
Drug-resistant mobile elements
We suspected that plasmid carrying was the cause of the difference in the ST540 resistance gene profile. Thus we uploaded ST540 strain contigs to the VRprofile2 pipeline to predict whether ST540 carried resistant plasmids. The results showed that five strains carried resistant plasmid Fig. 6. Analysis by blastn showed that these resistant plasmids were high similar to p2BJAB07104 (NC_021728.1) with 84% coverage and 100% identity. We spliced the plasmids and found that they all carried msr(E), armA, sul1, and mph(E) genes, which were not found on the chromosomes. None of the blaOXA−23 gene was located on the resistant plasmid. To study its genetic environment, we compared the ST540 strain contigs carrying blaOXA−23 gene with the transposon reference sequence (Tn2006 EF127491.1, Tn2007 EF059914.1, Tn2008 KP074966.1, Tn2009 CP097879.1) and found that the blaOXA−23 gene was located on Tn2006 (n = 4, 30.8%) and Tn2009 (n = 9, 69.2%%) Fig. 7. Tn2006 and Tn2009 share a common region, “OXA-23”. They also contain ISAba1. The two ISAba1 copies were inversely orientated in Tn2006 compared with being the same direction in Tn2009.
Fig. 6.
ST540 drug-resistant plasmids. Sequence comparison of plasmid p2BJAB07104 and other plasmids including pAb16630, pAb17179, pAb17282, pAb19271, pAb19277. BLASTN matches with an identity between 0 and 100% are colored in gradient
Fig. 7.
ST540 Transposons. The evolutionary relationships within ST540 are shown on the left, the transposons carried by each strain are shown on the right, and the direction of the arrow indicates the insertion sequence direction
Discussion
Due to its easy access to resistance genes, A.baumannii is considered a major threat to global public health [6]. In order to investigate the epidemical clones change and drug resistance mechanism of A.baumannii during COVID-19 and prevent the outbreak of infection caused by Multi-drug Resistant Acinetobacter baumannii (MDR-Ab), we retrospectively analyzed the molecular epidemiological characteristics and drug resistance mechanism of 95 A.baumannii strains at a hospital in Beijing for 3 years (2020–2022).
CHINET data showed that the resistance rate of Acinetobacter baumannii to carbapenem in China increased approximately twofold from 2005 (39%) to 2019 (79%) [36]. However, the resistance rate of carbapenems has decreased, from 79 to 71.9%, between 2019 and 2022 during the COVID-19 pandemic [36]. In this study, the resistance rate of carbapenem was only 62.1%, which was lower than the data (71.9%)in China. The variation of epidemic clones may be an important reason for the decrease in drug resistance rate. For example, there was a study reported that the variation of STs in a single hospital accompanied with the resistance rate to amikacin and tobramycin increased from 46.6 to 92% [37]. In this study, we found CRAB ST208 was still the main epidemic clone in China, reaching 22.1%, while in our hospital ST208 accounted for only 6.3%. In addition, we also found the sensitive A. baumannii ST373, which accounted for 8.4% of the total isolation rate. Thus, our study suggests that epidemiologic clonal changes may be important in influencing resistance rates. In China, the TGC resistance rate of A. baumannii was only 2% in 2022, which is much lower than other countries, for instance, Turkey, whose TGC resistance rate was about 81%, and Israel, 66%, Kuwait, 13.6% [36, 38, 39]. The treatment of MDR-Ab in our hospital usually involves tigecycline or colistin, as these two drugs have become the last line of defense in treating MDR-Abb [40]. In this study, the resistance rate of tigecycline is 12.6%, which is higher than the 4% rate in China [41], indicating a trend towards an increased level of tigecycline resistance. This trend is likely to pose a threat to the effectiveness of this last-resort drug. In order to prevent A. baumannii from becoming an incurable bug, the development of novel drugs is an urgent need. Our study provides additional bacterial data to support further investigation into therapeutic strategies for CRAB.
Our study found that ST540 became the main epidemic clone in our hospital, which was different from our previous report that ST195 and ST191 were the main STs in this hospital before 2014 [24]. Since the first report of ST540 in China in 2013 [42], it has increased in recent years in the northern China of Shandong Province [43] (12.8%) and Jilin Province [44](14.6%). Unlike these reports from China, we found for the first time that ST540 was the most prevalent clone in a single hospital. All ST540 strains isolated in this study were 100% resistant to carbapenems. CRAB is a worldwide problem because these strains are often resistant to all other commonly used antibiotics [45]. Although A.baumannii strains carrying blaOXA−23 and blaTEM−1D have been sporadically reported [46], the coexistence of blaOXA−23 and blaTEM−1D with other carbapenemase genes in A. baumannii is rarely reported. In this study, all ST540 strains carried blaOXA−23, blaOXA−66, blaADC−25 and blaTEM−1D genes, which may be the main cause of resistance to carbapenem. To our knowledge, this is the first report of a clinical A. baumannii ST540 isolates carrying blaOXA−23, blaOXA−66, blaADC−25 and blaTEM−1D genes in northern China. In addition, ST540 strains also carried resistance genes related to aminoglycoside, macrolide, phenicol, tetracycline, and sulfonamide. This finding is in agreement with previous observations reporting that most A. baumannii isolates carrying the blaOXA−23 gene also carry resistance genes to aminoglycosides and/or tetracyclines [45, 47].
Acinetobacter baumannii has the property of natural transformation, which can pass drug-resistant genes to other strains through the genome or mobile elements [48]. In our study, we also found internal differences in the resistance of ST540 due to the presence of [49]resistant plasmids carrying msrE, armA, sul1 and mphE genes, causing these strains to be resistant to macrolide, aminoglycoside and sulfonamide, in only five strains of ST540. The plasmid was unclassified plasmid and first identified on MDR-ZJ06 strain in China in 2011 [42]. Now, this plasmid could be found in some of the ST540 strains, suggesting that it may spread in A. baumannii through horizontal gene transfer. The blaOXA−23 genes are usually carried by transposons such as Tn2006, Tn2007, Tn2008, and Tn2009 [9]. Tn2006 is the most prevalent transposon worldwide and the only one that has been tested to be able to move independently and could be fund in many different chromosomal and plasmid contexts in distantly related A. baumannii strains [7]. According to a survey, the Tn2006-possessing strains belonged to various STs, whereas Tn2009-possessing strains were mainly belonged to ST191 [50]. However, our study found for the first time in ST540 that 69.2% of the strains carried Tn2009, indicating that Tn2009 is transferring among different A. baumannii strains.
Conclusion
During the COVID-19 pandemic, we investigated A. baumannii in a hospital in northern China and observed a rise in resistance to TGC during this time. ST540, carrying the resistance plasmid and Tn2009/Tn2006, became the predominant clone in our study unit. Our genomic analysis can help track outbreaks, detect the evolution of prevalent clones, and identify the presence of resistance genes. All these massages can help optimize antimicrobial stewardship and provide essential information for treatment decision-making. At the same time, our findings offer new epidemiological data that can be used to enhance infection control measures and clinical treatments in China.
Abbreviations
- A.baumannii
Acinetobacter Baumannii
- COVID-19
Corona Virus Disease 2019
- CRAB
Carbapenem-Resistant Acinetobacter Baumannii
- STs
Sequence Types
- MDR
Multidrug-Resistant
- XDR
Extensively Drug-Resistant
- PDR
Pan-Drug-Resistant
- WHO
World Health Organization
- MLST
Multilocus Sequence Typing
- GC1
Global Clone 1
- GC2
Global Clone 2
- TCC
Ticarcillin/Clavulanic Acid
- TZP
Piperacillin/Tazobactam
- CAZ
Ceftazidime
- CFP
Cefoperazone/Sulbactam
- FEP
Cefepime
- IPM
Imipenem
- MEM
Meropenem
- TOB
Tobramycin
- CIP
Ciprofloxacin
- LVX
Levofloxacin
- TGC
Tigecycline
- COL
Colistin
- MNO
Minocycline
- DOX
Doxycycline
- TMP
Trimethoprim/Sulfamethoxazole
- CLSI
Clinical and Laboratory Standards Institute
- SNPs
Single-Nucleotide Polymorphisms
- ML
Maximum Likelihood
- MIC
Minimal Inhibitory Concentration
- MDR-Ab
Multi-Drug Resistant Acinetobacter baumannii
Author contributions
HW* and BAL designed and supervised the experiments. XLH and NZN SMC, DYL performed experiments. HW, LYZ, XLY and CMB collected data; XLH and NZN interpreted and analyzed the data. XLH and NZN wrote the paper. All authors read and approved the final manuscript.
Funding
This work was supported by the State Key Laboratory of Pathogen and Biosecurity of China (SKLPBS2228).
Data availability
The whole genome sequencing data in this study have been deposited in Genbank under BioProject ID PRJNA1005007.
Declarations
Ethics approval and consent to participate
Microbiology isolation and identification were routine work in our hospital. Only strains that have been routinely collected for diagnosis were studied. No extra sampling from the patients was performed. No personal information about patients was requested. Therefore, a written personal informed consent and ethics committee approval were not required and Chinese law was strictly complied.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xinlin Huang, Nianzhi Ning, Hui Wang and Boan Li contributed equally to this work.
Contributor Information
Boan Li, Email: lba@263.net.
Hui Wang, Email: geno0109@vip.sina.com.
References
- 1.Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci. 2018;25(3):586–96. 10.1016/j.sjbs.2016.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55. 10.3389/fcimb.2017.00055 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Paterson DL, Bonomo RA. Multidrug-resistant gram-negative pathogens: the Urgent need for ‘Old’ polymyxins. Adv Exp Med Biol. 2019;1145:9–13. 10.1007/978-3-030-16373-0_2 [DOI] [PubMed] [Google Scholar]
- 4.Nasr P. Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. J Hosp Infect. 2020;104(1):4–11. 10.1016/j.jhin.2019.09.021 [DOI] [PubMed] [Google Scholar]
- 5.Li T, Luo D, Ning N, Liu X, Chen F, Zhang L, et al. Acinetobacter baumannii adaptation to the host pH microenvironment is mediated by allelic variation in a single residue of BauA protein. PNAS Nexus. 2023;2(4):pgad079. 10.1093/pnasnexus/pgad079 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27. 10.1016/S1473-3099(17)30753-3 [DOI] [PubMed] [Google Scholar]
- 7.Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40. 10.3201/eid1601.090852 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Huang ZY, Li J, Shui J, Wang HC, Hu YM, Zou MX. Co-existence of blaOXA-23 and blaVIM in carbapenem-resistant Acinetobacter baumannii isolates belonging to global complex 2 in a Chinese teaching hospital. Chin Med J (Engl). 2019;132(10):1166–72. 10.1097/CM9.0000000000000193 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom. 2019;5(10). [DOI] [PMC free article] [PubMed]
- 10.Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol. 2005;3(9):711–21. 10.1038/nrmicro1234 [DOI] [PubMed] [Google Scholar]
- 11.Nigro SJ, Hall RM. Structure and context of Acinetobacter transposons carrying the oxa23 carbapenemase gene. J Antimicrob Chemother. 2016;71(5):1135–47. 10.1093/jac/dkv440 [DOI] [PubMed] [Google Scholar]
- 12.Khongfak S, Thummeepak R, Leungtongkam U, Tasanapak K, Thanwisai A, Sitthisak S. Insights into mobile genetic elements and the role of conjugative plasmid in transferring aminoglycoside resistance in extensively drug-resistant Acinetobacter baumannii AB329. PeerJ. 2022;10:e13718. 10.7717/peerj.13718 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95(6):3140–5. 10.1073/pnas.95.6.3140 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Pérez-Losada M, Cabezas P, Castro-Nallar E, Crandall KA. Pathogen typing in the genomics era: MLST and the future of molecular epidemiology. Infect Genet Evol. 2013;16:38–53. 10.1016/j.meegid.2013.01.009 [DOI] [PubMed] [Google Scholar]
- 15.Bessell PR, Rotariu O, Innocent GT, Smith-Palmer A, Strachan NJ, Forbes KJ, et al. Using sequence data to identify alternative routes and risk of infection: a case-study of campylobacter in Scotland. BMC Infect Dis. 2012;12:80. 10.1186/1471-2334-12-80 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.De Francesco MA, Caracciolo S, Gargiulo F, Manca N. Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy. Eur J Clin Microbiol Infect Dis. 2012;31(8):1741–7. 10.1007/s10096-011-1495-4 [DOI] [PubMed] [Google Scholar]
- 17.Kong X, Chen T, Guo L, Zhou Y, Lu P, Xiao Y. Phenotypic and genomic comparison of dominant and nondominant sequence-type of Acinetobacter baumannii isolated in China. Front Cell Infect Microbiol. 2023;13:1118285. 10.3389/fcimb.2023.1118285 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Niu T, Guo L, Kong X, He F, Ru C, Xiao Y. Prevalent Dominant Acinetobacter baumannii ST191/195/208 strains in bloodstream infections have high Drug Resistance and Mortality. Infect Drug Resist. 2023;16:2417–27. 10.2147/IDR.S403604 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zarrilli R, Bagattini M, Migliaccio A, Esposito EP, Triassi M. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy. Ann Ig. 2021;33(5):401–9. [DOI] [PubMed] [Google Scholar]
- 20.Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakynthinos E, et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis. 2015;15:559. 10.1186/s12879-015-1297-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.McKay SL, Vlachos N, Daniels JB, Albrecht VS, Stevens VA, Rasheed JK, et al. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii in the United States, 2013–2017. Microb Drug Resist. 2022;28(6):645–53. 10.1089/mdr.2021.0352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Frenk S, Temkin E, Lurie-Weinberger MN, Keren-Paz A, Rov R, Rakovitsky N, et al. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. J Antimicrob Chemother. 2022;77(4):934–43. 10.1093/jac/dkac010 [DOI] [PubMed] [Google Scholar]
- 23.Kim SE, Choi SM, Yu Y, Shin SU, Oh TH, Kang SJ, et al. Replacement of the Dominant ST191 clone by ST369 among Carbapenem-Resistant Acinetobacter baumannii Bloodstream isolates at a Tertiary Care Hospital in South Korea. Front Microbiol. 2022;13:949060. 10.3389/fmicb.2022.949060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ning NZ, Liu X, Bao CM, Chen SM, Cui EB, Zhang JL, et al. Molecular epidemiology of bla (OXA-23) -producing carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China. BMC Infect Dis. 2017;17(1):14. 10.1186/s12879-016-2110-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455–77. 10.1089/cmb.2012.0021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–9. 10.1093/bioinformatics/btu153 [DOI] [PubMed] [Google Scholar]
- 27.Price MN, Dehal PS, Arkin AP. FastTree 2–approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3):e9490. 10.1371/journal.pone.0009490 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhou H, Zhang T, Yu D, Pi B, Yang Q, Zhou J, et al. Genomic analysis of the multidrug-resistant Acinetobacter baumannii strain MDR-ZJ06 widely spread in China. Antimicrob Agents Chemother. 2011;55(10):4506–12. 10.1128/AAC.01134-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Letunic I, Bork P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49(W1):W293–6. 10.1093/nar/gkab301 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Ribeiro-Gonçalves B, Francisco AP, Vaz C, Ramirez M, Carriço JA. PHYLOViZ Online: web-based tool for visualization, phylogenetic inference, analysis and sharing of minimum spanning trees. Nucleic Acids Res. 2016;44(W1):W246–51. 10.1093/nar/gkw359 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Florensa AF, Kaas RS, Clausen P, Aytan-Aktug D, Aarestrup FM. ResFinder - an open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes. Microb Genom. 2022;8(1). [DOI] [PMC free article] [PubMed]
- 32.Wang M, Goh YX, Tai C, Wang H, Deng Z, Ou HY. VRprofile2: detection of antibiotic resistance-associated mobilome in bacterial pathogens. Nucleic Acids Res. 2022;50(W1):W768–73. 10.1093/nar/gkac321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Darling AC, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14(7):1394–403. 10.1101/gr.2289704 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402. 10.1186/1471-2164-12-402 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006;34(Database issue):D32–6. 10.1093/nar/gkj014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hu F, Yuan L, Yang Y, Xu Y, Huang Y, Hu Y, et al. A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET). Front Cell Infect Microbiol. 2022;12:1075185. 10.3389/fcimb.2022.1075185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Jiang M, Chen X, Liu S, Zhang Z, Li N, Dong C, et al. Epidemiological analysis of Multidrug-Resistant Acinetobacter baumannii isolates in a Tertiary Hospital over a 12-Year period in China. Front Public Health. 2021;9:707435. 10.3389/fpubh.2021.707435 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In Vitro Activity of Tigecycline against Acinetobacter baumannii: Global Epidemiology and resistance mechanisms. Adv Exp Med Biol. 2016;897:1–14. [DOI] [PubMed] [Google Scholar]
- 39.Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother. 2011;23(1):13–6. 10.1179/joc.2011.23.1.13 [DOI] [PubMed] [Google Scholar]
- 40.Sun C, Yu Y, Hua X. Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front Cell Infect Microbiol. 2023;13:1141490. 10.3389/fcimb.2023.1141490 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, et al. In Vitro Activity of New β-Lactam-β-Lactamase inhibitor combinations and comparators against clinical isolates of Gram-negative Bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022;10(4):e0185422. 10.1128/spectrum.01854-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Zhu L, Yan Z, Zhang Z, Zhou Q, Zhou J, Wakeland EK, et al. Complete genome analysis of three Acinetobacter baumannii clinical isolates in China for insight into the diversification of drug resistance elements. PLoS ONE. 2013;8(6):e66584. 10.1371/journal.pone.0066584 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Shi X, Wang H, Wang X, Jing H, Duan R, Qin S, et al. Molecular characterization and antibiotic resistance of Acinetobacter baumannii in cerebrospinal fluid and blood. PLoS ONE. 2021;16(2):e0247418. 10.1371/journal.pone.0247418 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.You Q, Du X, Hu N, Zhang Y, Zhang N, Wang F, et al. Local characteristics of molecular epidemiolgy of Acinetobacter baumannii in Jilin province (northeast China). BMC Microbiol. 2023;23(1):19. 10.1186/s12866-023-02761-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48(10):6987–98. 10.1007/s11033-021-06690-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bharathi SV, Venkataramaiah M, Rajamohan G. Genotypic and phenotypic characterization of Novel sequence types of Carbapenem-Resistant Acinetobacter baumannii, with heterogeneous resistance determinants and targeted variations in Efflux Operons. Front Microbiol. 2021;12:738371. 10.3389/fmicb.2021.738371 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Lv W, Zhang X, Hou M, Han D, Li Y, Xiong W. Draft genome sequence of an OXA-23, OXA-66, ADC-25 and TEM-1D co-producing Acinetobacter baumannii ST195 isolated from a patient with neonatal pneumonia in China. J Glob Antimicrob Resist. 2019;16:1–3. 10.1016/j.jgar.2018.11.008 [DOI] [PubMed] [Google Scholar]
- 48.Liu LL, Ji SJ, Ruan Z, Fu Y, Fu YQ, Wang YF, et al. Dissemination of blaOXA-23 in Acinetobacter spp. in China: main roles of conjugative plasmid pAZJ221 and transposon Tn2009. Antimicrob Agents Chemother. 2015;59(4):1998–2005. 10.1128/AAC.04574-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Hu Y, Zhang X, Deng S, Yue C, Jia X, Lyu Y. Non-antibiotic prevention and treatment against Acinetobacter baumannii infection: are vaccines and adjuvants effective strategies? Front Microbiol. 2023;14:1049917. 10.3389/fmicb.2023.1049917 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Yoon EJ, Kim JO, Yang JW, Kim HS, Lee KJ, Jeong SH, et al. The blaOXA-23-associated transposons in the genome of Acinetobacter spp. represent an epidemiological situation of the species encountering carbapenems. J Antimicrob Chemother. 2017;72(10):2708–14. 10.1093/jac/dkx205 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The whole genome sequencing data in this study have been deposited in Genbank under BioProject ID PRJNA1005007.






